口服益生菌Familact对COPD患者呼吸障碍治疗的影响:一项随机对照试验
Mehdi Aghamohammadi1, Samad Ghodrati1, Nooshin Jalili1
1Department of Internal Medicine, School of Medicine, Vali-e-Asr Hospital, Zanjan University of Medical Sciences, Iran.
像Familact这样的口服益生菌可以改善慢性阻塞性肺病 (COPD) 患者的呼吸困难. 这项研究发现,随着Familact补充剂的使用,呼吸障碍得分 (MMRC和BORG) 显著改善.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 微生物学 微生物学
- 临床试验 临床试验
背景情况:
- 新兴研究表明,口服益生菌可以在呼吸系统疾病中增强免疫反应.
- 益生菌在治疗慢性阻塞性肺病 (COPD) 方面表现有前途.
研究的目的:
- 评估口服益生菌Familact,当添加到标准COPD护理时,是否可以改善呼吸障碍的管理.
- 在COPD患者中,Familact加标准治疗与单独标准治疗的比较.
主要方法:
- 一个单盲随机临床试验,涉及60名COPD患者.
- 参与者被随机分配到对照组 (标准护理) 和干预组 (标准护理+Familact) 三个月.
- 呼吸障碍的评估是使用博格尺度评分 (BORG) 和医学研究理事会修改呼吸障碍尺度评分 (MMRC) 进行的.
主要成果:
- 没有观察到FEV1的显著变化.
- 与对照组相比,干预组在MMRC和BORG得分上显示了统计学上显著的改善 (P < 0.01).
- 在各个时间点,在各组之间发现了BORG分数的显著差异.
结论:
- 一种口服益生菌Familact有效地缓解了COPD患者的呼吸障碍.
- BORG和MMRC得分的改善表明患者报告的结果有所改善.
- 益生菌是一种潜在的COPD管理的辅助疗法.
更多相关视频
09:20Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
